CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Heparin SCWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug343 Heparin Infusion Wiki 1.00
drug287 Enoxaparin/Lovenox Intermediate Dose Wiki 1.00
drug286 Enoxaparin Prophylactic Dose Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D013923 Thromboembolism NIH 0.71
D020246 Venous Thrombosis NIH 0.58
D013927 Thrombosis NIH 0.41

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID)

This study is being conducted to assess the effectiveness of intermediate versus prophylactic doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's usual standard of care but determining the dose of anticoagulation is based on physician preference. The investigators are conducting this study (a randomized trial with adaptive design employing cluster randomization) with the support of all of the ICUs to collect data in order to determine what should be the standard of care in terms of anticoagulation in these critically ill patients. The patients care will not be altered other than the choice of anticoagulation (both approved and used throughout the hospital as standard of care) based on the ICU bed they are assigned. Patient data will be collected until discharge.

NCT04367831 COVID-19 Venous Thromboses Arterial Thrombosis Drug: Enoxaparin Prophylactic Dose Drug: Heparin Infusion Drug: Heparin SC Drug: Enoxaparin/Lovenox Intermediate Dose
MeSH:Thrombosis Thromboembolism Venous Thrombosis
HPO:Deep venous thrombosis Thromboembolism Venous thrombosis

Primary Outcomes

Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).

Measure: Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU

Time: Discharge from ICU or 30 days

Secondary Outcomes

Description: Composite of being alive and without clinically-relevant venous or arterial thrombotic events at discharge from ICU (without transfer to another ICU or palliative care unit/hospice) or at 30 days (if ICU duration lasted 30 days or longer).

Measure: Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events

Time: Discharge from hospital or 30 days

Description: Length of stay measured in days.

Measure: ICU Length of Stay

Time: Discharge from ICU or 30 days

Description: The impact of intermediate-dose anti-coagulation compared with prophylactic anti-coagulation on rates of acute kidney injury and renal recovery in the ICU will be measured with the total number of patients who need of renal replacement therapy in the ICU.

Measure: Total Number of Patients with the Need for Renal Replacement Therapy in the ICU

Time: Discharge from hospital or 30 days

Description: Major bleeding will be assessed by BARC criteria, also explored by International Society on Thrombosis and Haemostasis (ISTH) and Thrombolysis in Myocardial Infarction (TIMI) criteria.

Measure: Total Number of Patients with Major bleeding in the ICU

Time: Discharge from hospital or 30 days

Description: Length of stay measured in days.

Measure: Hospital Length of Stay

Time: Discharge from hospital or 30 days


Related HPO nodes (Using clinical trials)